Baricitinib

  • TRADE NAME: Olumiant (Eli Lilly and Co)
  • INDICATIONS: treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.
  • CLASS: Janus kinase (JAK) inhibitor
  • HALF-LIFE: ~12 hours

FDA APPROVAL DATE: 05/31/2018

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

None known

PREGNANCY CATEGORY: N/A
Insufficient data to inform a drug-associated risk for major birth defects or miscarriage

SERIOUS INFECTIONS, MALIGNANCY, AND THROMBOSIS

See full prescribing information for complete boxed warning

Our database has 37 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
MUCOSAL
CENTRAL NERVOUS SYSTEM
GASTROINTESTINAL/HEPATIC
RESPIRATORY
ENDOCRINE/METABOLIC
GENITOURINARY
HEMATOLOGIC
OTHER


Page last updated 09/19/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric